


# Stabilis



## Cefoxitin sodium



Noms commerciaux

Altraxitina	Portugal
Cefociclin	Italie
Cefox	Brésil
Cefoxit	Brésil
Cefoxitin	Australie, Autriche, Canada, Etats Unis d'Amérique
Cefoxitina	Argentine, Brésil, Colombie, Espagne, Portugal
Cefton	Brésil
Destrepen	Grèce
Foxitin	Arabie Saoudite, Emirats Arabes Unis
Kefox	Grèce
Mefoxil	Grèce
Mefoxin	Australie, Etats Unis d'Amérique, Italie, Luxembourg, Pays bas
Mefoxitin	Allemagne, Autriche, Suisse, Vénézuela
Metaptyl	Suède
Renoxitin	Grande Bretagne
Tifox	Italie



### Stabilité des solutions

Formulation	Stabilité	Concentration	Température	Protection	Durée	Classement	Autres	Code
?	?	[ ]	- +	?	?	?	!	?
?	?	20 mg/ml	25°C	☀	48	✓		418
PVC	?	40 mg/ml	-20°C	☀	30	☾		440
PVC	?	20 mg/ml	-20°C	☀	30	☾		576
PP	?	125 mg/ml	20-25°C	☀	12	✓		4634
PI	?	5 & 60 mg/ml	4°C	☀	10	☾		604



## Stabilité en mélange

		20 mg/ml	25°C		Clindamycin phosphate : 9 mg/ml	48		418
		5 mg/ml	25°C		Magnesium sulfate : 10 & 20 mg/ml	20		630
		30 mg/ml	25°C		Metronidazole : 5 mg/ml	2		631
		30 mg/ml	25°C		Metronidazole : 5 mg/ml	2		631
		30 mg/ml	5°C		Metronidazole : 5 mg/ml	12		631
		10 & 20 mg/ml	25°C		Aztreonam : 10 & 20 mg/ml	12		19
		10 & 20 mg/ml	4°C		Aztreonam : 10 & 20 mg/ml	7		19



## Compatibilités

	Cefoxitin sodium : 0,3 mg/ml	
		Cefoxitin sodium Amikacin sulfate
	Cefoxitin sodium : 20 mg/ml Anidulafungin : 0.5 mg/ml	
	Cefoxitin sodium : 20 mg/ml	
	Cefoxitin sodium : 200 mg/ml	
	Cefoxitin sodium : 95 mg/ml	
	Cefoxitin sodium : 20 mg/ml	
	Cefoxitin sodium : 100 mg/ml	
	Cefoxitin sodium : 20 mg/ml Aciclovir sodium : 5 mg/ml	
	Cefoxitin sodium : 20 mg/ml Amifostine : 10 mg/ml	
	Cefoxitin sodium : 20 mg/ml Amifostine : 10 mg/ml	
	Cefoxitin sodium : 100 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml	
	Cefoxitin sodium : 20 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml	
	Cefoxitin sodium : 20 mg/ml Aztreonam : 40 mg/ml	
	Cefoxitin sodium : 10 & 20 mg/ml Aztreonam : 10 & 20 mg/ml	
	Cefoxitin sodium : 20 mg/ml Bivalirudin : 5 mg/ml	

		Cefoxitin sodium : 100 mg/ml Caffeine : 10 mg/ml		3964
		Cefoxitin sodium : 10 mg/ml Cimetidine hydrochloride : 3 mg/ml		1201
		Cefoxitin sodium : 20 mg/ml Cisatracurium besylate : 0.1 mg/ml		299
		Cefoxitin sodium : 20 mg/ml Cisatracurium besylate : 2 & 5 mg/ml		299
		Cefoxitin sodium : 20 mg/ml Clindamycin phosphate : 9 mg/ml		418
		Cefoxitin sodium Clindamycin phosphate		3526
		Cefoxitin sodium : 100 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Cefoxitin sodium : 20 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Cefoxitin sodium : 200 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
		Cefoxitin sodium : 10 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Cefoxitin sodium : 20 mg/ml Docetaxel : 0.9 mg/ml		1754
		Cefoxitin sodium : 20 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Cefoxitin sodium Erythromycin lactobionate		3674
		Cefoxitin sodium : 20 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Cefoxitin sodium : 20 mg/ml Famotidine		397
		Cefoxitin sodium : 20 mg/ml Famotidine : 2 mg/ml		215
		Cefoxitin sodium : 20 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Cefoxitin sodium : 20 mg/ml Filgrastim : 30 µg/ml		244
		Cefoxitin sodium : 40 mg/ml Fluconazole : 2 mg/ml		496
		Cefoxitin sodium : 40 mg/ml Foscarnet sodium : 24 mg/ml		73
		Cefoxitin sodium : 20 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Cefoxitin sodium Gentamicin sulfate		3643
		Cefoxitin sodium Gentamicin sulfate		3520
		Cefoxitin sodium : 20 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Cefoxitin sodium : 20 mg/ml Hetastarch : 60 mg/ml		1721
		Cefoxitin sodium : 20 mg/ml Hetastarch : 60 mg/ml		472

		Cefoxitin sodium : 20 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
		Cefoxitin sodium : 100 mg/ml Imipenem - cilastatin sodium : 50 mg/ml		4389
		Cefoxitin sodium : 20 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Cefoxitin sodium : 20 mg/ml Linezolid : 2 mg/ml		1925
		Cefoxitin sodium : 20 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml		1047
		Cefoxitin sodium : 5 mg/ml Magnesium sulfate : 10 & 20 mg/ml		630
		Cefoxitin sodium : 100 mg/ml Meropenem : 50 mg/ml		4319
		Cefoxitin sodium : 30 mg/ml Metronidazole : 5 mg/ml		1035
		Cefoxitin sodium Metronidazole		3594
		Cefoxitin sodium : 30 mg/ml Metronidazole : 5 mg/ml		631
		Cefoxitin sodium : 20 mg/ml Morphine sulfate : 1 mg/ml		405
		Cefoxitin sodium : 40 mg/ml Morphine sulfate : 1 mg/ml		406
		Cefoxitin sodium N-acetylcysteine : 200 mg/ml		3766
		Cefoxitin sodium : 100 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Cefoxitin sodium : 20 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Cefoxitin sodium Pantoprazole sodium		2090
		Cefoxitin sodium : 100 mg/ml Paracetamol : 10 mg/ml		3571
		Cefoxitin sodium : 100 mg/ml Paracetamol : 10 mg/ml		4742
		Cefoxitin sodium : 20 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Cefoxitin sodium : 20 mg/ml Pentamidine isetionate : 3 mg/ml		275
		Cefoxitin sodium : 20 mg/ml Pethidine hydrochloride : 10 mg/ml		405
		Cefoxitin sodium : 40 mg/ml Pethidine hydrochloride : 10 mg/ml		406
		Cefoxitin sodium : 20 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Cefoxitin sodium : 20 mg/ml Propofol : 10 mg/ml		300
		Cefoxitin sodium : 20 mg/ml Ranitidine hydrochloride : 1 mg/ml		2355
		Cefoxitin sodium : 20 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59

	Cefoxitin sodium : 100 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
	Cefoxitin sodium : 20 mg/ml Sulbactam/durlobactam : 15/15 mg/ml	▲	4801
	Cefoxitin sodium : 20 mg/ml Teniposide : 0.1 mg/ml	◆	905
		▲	3767
	Cefoxitin sodium : 20 mg/ml Thiotepa : 1 mg/ml	◆	249
	Cefoxitin sodium : 1 mg/ml Vancomycin hydrochloride : 20 mg/ml	◆	1674
		◆	1674
	Cefoxitin sodium : 1 >> 180 mg/ml Vancomycin hydrochloride : 2 mg/ml	◆	1674
		◆	1674
	Cefoxitin sodium : 4 mg/ml Verapamil hydrochloride : 0.08 mg/ml	▲◆	1057



## Voie d'administration



## Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
19	Revue	Bell RG, Lipford LC, Massanari MJ, Riley CM. Stability of intravenous admixtures of aztreonam and cefoxitin, gentamicin, metronidazole, or tobramycin. Am J Hosp Pharm 1986 ; 43: 1444-1453.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.

198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
275	Revue	Lewis JD, El-Gendy A. Cephalosporin-pentamidine isethionate incompatibilities. Am J Health-Syst Pharm 1996 ; 53: 1461-1462.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
397	Revue	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
405	Revue	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
406	Revue	Smythe MA, Patel MA, Gasloli RA. Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 819-820.
418	Revue	Bosso JA, Townsend RJ. Stability of clindamycin phosphate and ceftizoxime sodium, cefoxitine sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions. Am J Hosp Pharm 1985 ; 42: 2211-2214.
440	Revue	Stiles ML, Tu YH, Allen LV. Stability of cefazolin sodium, cefoxitin sodium, ceftazidime, and penicillin G sodium in portable pump reservoirs. Am J Hosp Pharm 1989 ; 46: 1408-1412.

472	Revue	Wohlford JG, Fowler MD. Visual compatibility of hetastarch with injectable critical-care drugs. Am J Hosp Pharm 1989 ; 46: 995-996.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
576	Revue	Holmes CJ, Ausman RK, Walter CW, Kundsinn RB. Activity of antibiotic admixtures subjected to different freeze-thaw treatments. Drug Intell Clin Pharm 1980 ; 14: 353-357.
604	Laboratoire	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
630	Revue	Das Gupta V, Stewart KR. Stability of metronidazole and ten antibiotics when mixed with magnesium sulphate solutions. J Clin Hosp Pharm 1985 ; 10: 67-72.
631	Revue	Das Gupta V, Stewart KR. Chemical stabilities of hydrocortisone sodium succinate and several antibiotics when mixed with metronidazole injection for intravenous infusion. J Parenter Sci Technol 1985 ; 39: 145-148.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	Revue	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
999	Revue	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1035	Revue	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1047	Revue	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1201	Revue	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.

1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1674	Revue	Trissel LA, Gilbert DL, Martinez JF. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm 1998 ; 33: 1515-1522.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Revue	Trissel LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2355	Revue	Inagaki K, Miyamoto Y, Kurata N, Nakane S, Gill M.A, Nishida M. Stability of ranitidine hydrochloride with cefazolin sodium, cefbuperazone sodium, cefoxitin sodium and cephalotin sodium during simulated Y-site administration. Int J Pharm Compound 2000 ; 4, 2: 150-153.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3520	Laboratoire	Cidomycin - Summary of product Characteristics. Sanofi 2011



3526	Laboratoire	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3549	Laboratoire	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3571	Revue	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3594	Laboratoire	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013
3643	Laboratoire	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévamisentan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4634	Revue	Loeuille G, Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4693	Revue	Shen H, Fu Y, Chen Y, Xia W, Jia Z, Yu Q, Zhang L, Han L. Compatibility and Stability of Ten Commonly Used Clinical Drugs in Pediatric Electrolyte Supplements Injection. Drug Design Dev Ther 2022 ;16:1433-1440.
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
------	-------	--



# Dictionnaire

	Antibiotique		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Verre
	NaCl 0,9% ou glucose 5%		Lumière
	Heure		Polyvinyl chlorure
	Eau pour préparation injectable		A l'abri de la lumière
	Jour		Glucose 5%
	Seringue polypropylène		Elastomère en polyisoprène
	Stabilité en mélange		Solvant
	Molécule		Aucun
	Non précisée		Compatibilités
	Compatible		NaCl 0.225 % + glucose 3.75%
	Instabilité chimique		Incompatible
	Nutrition parentérale (mélange binaire)		Nutrition parentérale (mélange ternaire)
<b>RL</b>	Ringer lactate		Turbidité immédiate
	Chlorure de sodium 0,9%		Incompatibilité non précisée
	Précipitation immédiate		Solvant spécifique
	Précipitation en 1 heure		Précipitation en 4 heures
	Changement de couleur		Turbidité en 4 heures
	Voie d'administration		Intraveineuse
	Perfusion intraveineuse		Perfusion continue
	Intramusculaire		Bibliographie
	Dictionnaire		